User:Jeremy S. Myers: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
No edit summary |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 20: | Line 20: | ||
==Research interests== | ==Research interests== | ||
<!-- Feel free to add brief descriptions to your research interests as well --> | <!-- Feel free to add brief descriptions to your research interests as well --> | ||
# Targeted Mass Spectrometry-based | # Targeted Mass Spectrometry-based Proteomics | ||
# Targeted Therapeutics | # Targeted Therapeutics | ||
Line 32: | Line 32: | ||
==Selected Protocols== | ==Selected Protocols== | ||
*[[Myers:EGFR_IP]] | *[[Myers:EGFR_IP]] | ||
*[[Myers:synchronization]] |
Latest revision as of 08:20, 14 August 2008
Contact Info
- Jeremy S. Myers, Ph.D.
- AstraZeneca Fellow
- Advanced Targeted Proteomics Team Leader
- Vanderbilt University School of Medicine
- Mass Spectrometry Research Center
- Nashville, TN, U.S.A.
- jeremy.myers@vanderbilt.edu
for more information visit: http://www.advancedtargetedproteomics.com
Education
- 2003-2007 Postdoctoral Fellow
- 2003 Ph.D., Louisiana State University
- 1999 B.S., Bucknell University
Research interests
- Targeted Mass Spectrometry-based Proteomics
- Targeted Therapeutics
Publications (since 2007)
- Myers JS, Zhao R, Xu X, Ham AJ, Cortez D. Cyclin-dependent kinase 2 dependent phosphorylation of ATRIP regulates the G2-M checkpoint response to DNA damage. Cancer Res. 2007 Jul 15;67(14):6685-90. PMID: 17638878